Steve Wenglowsky
Blueprint Medicines (United States)(US)
Publications by Year
Research Areas
Melanoma and MAPK Pathways, Protein Kinase Regulation and GTPase Signaling, HER2/EGFR in Cancer Research, Asymmetric Synthesis and Catalysis, Organometallic Complex Synthesis and Catalysis
Most-Cited Works
- → Discovery of Danoprevir (ITMN-191/R7227), a Highly Selective and Potent Inhibitor of Hepatitis C Virus (HCV) NS3/4A Protease(2013)140 cited
- → Three-Component Intramolecular Two-Alkyne Annulations of Fischer Carbene Complexes: New Strategies for Steroid Synthesis(1994)69 cited
- → Pyrazolopyridine Inhibitors of B-RafV600E. Part 1: The Development of Selective, Orally Bioavailable, and Efficacious Inhibitors(2011)66 cited
- → Pyrazolopyridine inhibitors of B-RafV600E. Part 2: Structure–activity relationships(2011)56 cited
- → Biomimetic Macrocycle-Forming Diels−Alder Reaction of an Iminium Dienophile: Synthetic Studies Directed Toward Gymnodimine(2005)54 cited
- → Potent and Selective Aminopyrimidine-Based B-Raf Inhibitors with Favorable Physicochemical and Pharmacokinetic Properties(2012)47 cited
- → Pyrazolopyridine inhibitors of B-RafV600E. Part 3: An increase in aqueous solubility via the disruption of crystal packing(2011)46 cited
- → Tandem Diels-Alder/double intramolecular two-alkyne annulations of Fischer carbene complexes: a one-pot construction of all four rings of the steroid ring system(1991)43 cited
- → An Asymmetric Synthesis of Optically Pure α,α-Disubstituted Amino Aldehydes, α,α-Disubstituted Amino Acids, and Sterically Demanding Dipeptides(1998)34 cited
- → Pyrazolopyridine inhibitors of B-RafV600E. Part 4: Rational design and kinase selectivity profile of cell potent type II inhibitors(2012)29 cited